Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in advanced gynecological carcinoma
NCT04870177Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Apr 2021
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in ovarian cancer, Cervical Cancer (CC), endometrial cancer (EC), sponsored by Akeso, Inc.. Started Apr 2021; status: completed.
02
Drugs
ivonescimab
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04870177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870177.